Literature DB >> 8852980

Lactobacilli and bacteremia in southern Finland, 1989-1992.

M Saxelin1, N H Chuang, B Chassy, H Rautelin, P H Mäkelä, S Salminen, S L Gorbach.   

Abstract

In order to assess the potential of lactobacilli to cause serious infections, we studied the prevalence of bacteremia due to Lactobacillus species during a 4-year period (1989-1992) in southern Finland, which has a population of about 2.5 million. Among 3,317 blood culture isolates, lactobacilli were identified in eight patients, five of whom had a severe disease predisposing to bacteremic complications. The eight strains isolated were identified to the species level and typed by carbohydrate fermentation tests and by direct sequencing of enzymatically amplified 16S rRNA. The results did not provide evidence that any particular species or subspecies of Lactobacillus was the cause of the infections; no infections caused by isolates similar to the recently introduced dairy probiotic strain, Lactobacillus GG (ATCC 53103), were observed. The data show an infrequent association of lactobacilli with bacteremic infections in spite of the ubiquitous presence of these organisms in the gastrointestinal tract and their widespread consumption in fermented milks; thus, there is strong evidence that their pathogenic potential is very low.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852980     DOI: 10.1093/clinids/22.3.564

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Cyclopropane fatty acid synthase mutants of probiotic human-derived Lactobacillus reuteri are defective in TNF inhibition.

Authors:  Sara E Jones; Kristi Whitehead; Delphine Saulnier; Carissa M Thomas; James Versalovic; Robert A Britton
Journal:  Gut Microbes       Date:  2011-03-01

2.  In vitro adhesion and platelet aggregation properties of bacteremia-associated lactobacilli.

Authors:  P V Kirjavainen; E M Tuomola; R G Crittenden; A C Ouwehand; D W Harty; L F Morris; H Rautelin; M J Playne; D C Donohue; S J Salminen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 4.  A potential role of probiotics in colorectal cancer prevention: review of possible mechanisms of action.

Authors:  Esther Swee Lan Chong
Journal:  World J Microbiol Biotechnol       Date:  2013-09-26       Impact factor: 3.312

5.  Importance of Molecular Methods to Determine Whether a Probiotic is the Source of Lactobacillus Bacteremia.

Authors:  Alla Aroutcheva; Julie Auclair; Martin Frappier; Mathieu Millette; Karen Lolans; Danielle de Montigny; Serge Carrière; Stephen Sokalski; William E Trick; Robert A Weinstein
Journal:  Probiotics Antimicrob Proteins       Date:  2016-03       Impact factor: 4.609

6.  Does Lactobacillus GG prevent antibiotic-associated diarrhea in children?: Part A: Evidence-based answer and summary.

Authors:  Bradley C Johnston; Kristie Cramer; Sunita Vohra
Journal:  Paediatr Child Health       Date:  2005-03       Impact factor: 2.253

Review 7.  Ecological control of the gastrointestinal tract. The role of probiotic flora.

Authors:  S Bengmark
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

Review 8.  Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases.

Authors:  J P Cannon; T A Lee; J T Bolanos; L H Danziger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

9.  Colonization of congenitally immunodeficient mice with probiotic bacteria.

Authors:  R D Wagner; T Warner; L Roberts; J Farmer; E Balish
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

10.  Lactobacillus species identification, H2O2 production, and antibiotic resistance and correlation with human clinical status.

Authors:  A Felten; C Barreau; C Bizet; P H Lagrange; A Philippon
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.